Innovation Spirits
We have independently developed 10 minimally invasive interventional treatment solutions targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. All products are based on our original innovation and possess global patents and independent intellectual property rights.

AlginSys, our proprietary myocardial injectable biopolymer product, is designed to prevent the progression of advanced heart failure.